Back to dashboard
CommercialDocumentationMedium impact

08.01.05m, Carfilzomib (Kyprolis®)

Independence Blue Cross·Oncology, Pharmacy·Pharmacy
Effective date
Nov 17, 2025
We identified it
Jun 19, 2026
Days to comply
—

Summary

Policy 08.01.05m for Carfilzomib (Kyprolis®) has been updated effective 11/17/2025 with changes to Medical Necessity Criteria and Medical Coding requirements. The billing team must review and implement updated medical necessity documentation standards and billing code guidance for this chemotherapy agent to ensure claim compliance.

Action Required

Action needed
By 11/17/2025: Billing team must obtain and review the full policy text from the provided URL (https://medpolicy.ibx.com/ibc/Commercial/Pages/Site-Activity-View.aspx?FilterField1=MPSiteActivityLogMonth&FilterValue1=11&FilterField2=MPSiteActivityLogYear&FilterValue2=2025#commercial-08-01-05m) to identify specific Medical Necessity Criteria and Medical Coding changes for Carfilzomib (Kyprolis®). Update billing system rules, prior authorization workflows, and provider documentation templates accordingly. Communicate changes to oncology providers and ensure claims submitted after 11/17/2025 comply with new criteria. Claims submitted without adherence to updated medical necessity requirements will be denied.

Related policy hubs